TAT Congress series
Get a glimpse of future cancer therapies at the annual TAT congress
TAT provides a forum for in-depth discussion of emerging targeted agents for the treatment of cancer. The TAT series was established in 2002 and is offered by the NDDO Education Foundation, in a partnership with the European Society for Medical Oncology (ESMO). TAT 2012 is co-sponsored by the National Cancer Institute (NCI) of the USA.
TAT meetings are characterized by:
- Focus on emerging innovative agents with a cancer-specific molecular target
- Top-level international faculty, warranting high scientific standards
- Educational value for medical specialists and drug development professionals in oncology
- A completely plenary program allowing delegates to focus and not miss anything;
- Opportunities to present new research findings in a setting with the world's leading oncology phase 1 investigators
- Overseeable meetings with excellent opportunities for interactions with colleagues
- Attention to methodological and regulatory issues in anticancer drug development.
TAT meetings attract a mix of professionals with different backgrounds and roles in academia, industry and governmental agencies, all having a profound interest in the development of innovative cancer therapies.
TAT congresses are held annually in Europe, with the venue alternating between Paris (odd years) and Amsterdam (even years). TAT meetings are usually held in the first half of March. The next meeting will be TAT 2013 in Paris, march 4-6, 2013.
TAT Congress, number one in phase 1 !
